Poster Session 1
James D. Toppin, MD, MPH
Ochsner Health
New Orleans, Louisiana, United States
Shannon McCloskey, MD
Fellow
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Meena Mishra, PhD
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Mariella Gastanaduy, PhD
Ochsner Clinic
New Orleans, Louisiana, United States
Talia Suner, MD
Maternal Fetal Medicine Fellow
Ochsner Clinic
New Orleans, Louisiana, United States
Joseph R. Biggio, Jr., MD, MSc (he/him/his)
System Chair, Women's Services
Ochsner Health
New Orleans, Louisiana, United States
Frank B. Williams, MD, MPH (he/him/his)
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Syphilis rates have sharply increased in the United States over the past decade, increasing the number of people entering pregnancy with a history of syphilis. Despite well-established and effective treatments, congenital syphilis (CS) has likewise increased over that time. We aim to compare rate of CS among pregnancies with and without history of cured syphilis.
We performed a retrospective cohort study of singleton or twin pregnancies care from 2015 to 2023 at a large regional health system. Historical and prenatal laboratory values classified pregnancies as either history of syphilis or no history of syphilis. Patients with new diagnosis of syphilis at initiation of pregnancy care and those with initial prenatal rapid plasmin reagin (RPR) titer ≥ 1:8 were excluded. Pregnancies were stratified based on the history of adequately treated syphilis infection before pregnancy. Patients with history of syphilis and RPR < 1:8 were classified as serofast. Primary outcome was CS, defined by Centers for Disease Control case criteria. Secondary outcome was pregnancies with new or reinfection. Subanalysis evaluated for odds of CS among serofast patients. Chi square or T-test were used evaluate demographics and outcomes.
History of syphilis before pregnancy is associated with a dramatically increased risk of maternal reinfection and congenital syphilis, particularly among serofast patients.